o2h Ventures is excited to announce its achievement as the Runner-Up at the prestigious and highly competitive Growth Investor Awards 2023 in the Best EIS Manager – Specialist category.
The category acknowledges and celebrates outstanding investment managers in the Enterprise Investment Scheme (EIS) with a specialist focus on a particular area of underlying investments. The evaluation was based on assessing the success across business performance, investment inflows, impact on investors, adviser relations, and overall impact.
o2h Ventures deeply believe in the immense potential of the UK biotech sector and its pivotal role in making Britain a scientific Superpower by 2023. As a leading biotech specialist fund manager established in the heart of the biotech community, we are dedicated to nurturing and supporting early-stage biotech companies in the UK.
We have curated a robust and diverse s/eis portfolio within the biotech sector for our valued investors. Currently, we are invested in 28 companies spanning biotech therapeutics and the intersection between biotechnology and AI/ML. For a deeper understanding of our portfolio, please see https://o2hventures.com/portfolio.
“It was a well-run event with over 500 people in attendance with many of the largest fund managers in attendance. We are of course happy to be recognised for the hard work that we have put in throughout this year and aim to do one better next year! – Sunil Shah, CEO at o2h Ventures
About the Growth Investor Awards 2023
Celebrating the role of the UK SME investment community in job and wealth creation, the Growth Investor Awards recognise those enabling start-up and ‘scale-up’ businesses to realise their full potential and drive Britain’s economic recovery.
Open to both companies and individuals, these Awards honour all those involved in putting investment to work in high-potential businesses – from those providing investment or helping to source it to those best optimising growth capital to scale.
To learn more about Growth Investor Awards, please visit, https://growthinvestorawards.com/
About o2h Ventures
The o2h Ventures ‘Human Health’ SEIS and KI EIS funds make tax-efficient investments in Pre-Seed and Seed stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare.
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.
For more information or to invest in the fund, please visit www.o2hventures.com
